Rubric Capital Management LP Has $32.48 Million Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Rubric Capital Management LP increased its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 25.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,680,028 shares of the company’s stock after purchasing an additional 943,226 shares during the quarter. Rubric Capital Management LP owned approximately 1.23% of GoodRx worth $32,479,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd increased its stake in shares of GoodRx by 260.7% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock worth $308,000 after purchasing an additional 32,104 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of GoodRx by 5.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after buying an additional 26,262 shares during the last quarter. Quest Partners LLC bought a new position in shares of GoodRx during the 3rd quarter worth approximately $160,000. CWA Asset Management Group LLC acquired a new position in shares of GoodRx during the 3rd quarter worth approximately $370,000. Finally, Raymond James & Associates raised its stake in GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock valued at $2,734,000 after acquiring an additional 267,951 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Trading Down 2.7 %

GDRX stock opened at $4.76 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company’s fifty day simple moving average is $6.11 and its 200 day simple moving average is $7.29. GoodRx Holdings, Inc. has a 12-month low of $4.09 and a 12-month high of $9.26.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.17% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

GDRX has been the topic of several research reports. Barclays decreased their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a research report on Friday, August 9th. UBS Group decreased their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Finally, Citigroup dropped their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.86.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.